MRNS Marinus Pharmaceuticals Inc.

3.82
-0.16  -4%
Previous Close 3.98
Open 3.97
Price To Book 2.94
Market Cap 200622630
Shares 52,519,013
Volume 485,836
Short Ratio
Av. Daily Volume 764,781

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Data due 1H 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 trial initiation announced June 19, 2018.
Ganaxolone
CDKL5 disorder
Phase 2 data due 1H 2019
Ganaxolone - oral (Amaryllis)
Postpartum depression
Phase 3 initiation announced March 6, 2019 with data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy

Latest News

  1. Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
  2. Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
  3. Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
  4. Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
  5. Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
  6. Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why
  7. Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
  8. Main Line biopharm CEO stepping down
  9. Marinus Announces Leadership Transition
  10. Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
  11. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  12. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  13. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
  14. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  15. Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
  16. Marinus Pharmaceuticals plans $45M stock sale
  17. Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  18. Here's Why Marinus Pharmaceuticals Is Sinking Today
  19. The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
  20. Marinus Pharmaceuticals Announces Public Offering of Common Stock